A clinical-stage immuno-oncology company with the potential to significantly disrupt the current cell therapy landscape. The Company is developing a portfolio of non-genetically modified, multi-antigen T cell therapies, which are able to recognize and kill heterogeneous tumors more effectively than conventional single-antigen CAR-T/TCR approaches. Compared to current engineered CAR-T therapies, Marker's products could potentially be less expensive, easier to manufacture, be less toxic and show clinical benefit with less cell volume and faster administration time.
Marker's current MultiTAA cell therapy is looking to initiate a Phase II study in AML in 2020 with enrollment completion anticipated in 2H20. Marker announced an updated study protocol for the Ph 2 trial in February 2020. The company also has a T-cell vaccine program, currently being studied in breast cancer.
US - West South Central
Phase l or ll
3200 Southwest Fwy #2240, Phoenix Tower
Houston, TX 77027
Top 10 Holders of Marker Therapeutics, Inc.
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by